The Signal: Kivu Bioscience

Published

About this Series

The Signal

The Signal is Nasdaq’s editorial business news series, showcasing the leading companies that are moving markets. Episodes feature candid conversations with founders and CEOs across industries, unpacking the latest technologies, innovations, and applications that are driving change across the economy.

In this episode of The Signal, Kivu Bioscience CEO Mohit Trikha discusses the company's mission to develop next-generation antibody-drug conjugates that deliver more precise, effective, and well-tolerated cancer therapies. He shares how Kivu is advancing a differentiated oncology pipeline, the science behind its innovative ADC platform, and the milestones driving the company's next phase of growth.

Nasdaq Watch

See what's playing at Nasdaq

Watch Now